|  | Cancer | Lymphoma

Mantle Cell Lymphoma (MCL): Symptoms, Diagnosis, Staging, and Treatment Overview

Mantle Cell Lymphoma (MCL) is a distinct, aggressive B-cell non-Hodgkin lymphoma (5–7% of NHL) characterized by the t(11;14)(q13;q32) translocation causing cyclin D1 overexpression. Median age ~65–70; male predominance (~2:1).

Clinical Presentation

  • Generalized lymphadenopathy (cervical, axillary, inguinal)
  • B symptoms: Fever, drenching night sweats, >10% weight loss
  • Extranodal involvement: GI tract (lymphomatous polyposis), Waldeyer's ring, bone marrow, spleen, liver
  • Leukemic phase: Circulating lymphoma cells (often mistaken for CLL)
  • Constitutional: Fatigue, early satiety (splenomegaly), abdominal discomfort

Diagnostic Workup

  • Excisional lymph node biopsy: Architecture + IHC (CD5+, CD20+, Cyclin D1+, SOX11+)
  • FISH/karyotype: Confirm t(11;14); assess complexity (prognostic)
  • CT/PET-CT: Staging (Ann Arbor)
  • Bone marrow biopsy: Involvement pattern (nodular vs. diffuse)
  • Baseline labs: CBC, LDH, β2-microglobulin, renal/hepatic function, viral serologies
  • MIPI/MIPI-c: Prognostic indices (age, ECOG, LDH, WBC, Ki-67)

Treatment by Risk/Stage

Early Stage (I–II, Non-Bulky) — Rare

  • Radiation therapy ± brief chemoimmunotherapy

Advanced Stage — Fit Patients

  • Induction: High-intensity chemoimmunotherapy (R-CHOP, VR-CAP, Nordic MCL2/3, R-HyperCVAD) + rituximab
  • Consolidation: Autologous stem cell transplant (ASCT) in first remission — standard for eligible patients
  • Maintenance: Rituximab q2–3 months × 2–3 years (prolongs PFS)

Advanced Stage — Unfit/Older Patients

  • Bendamustine-rituximab (BR) ± cytarabine
  • BTK inhibitor-based regimens (ibrutinib/acalabrutinib/zanubrutinib + rituximab ± venetoclax) — increasing frontline use
  • Clinical trials preferred

High-Risk Features (Blastoid/Pleomorphic, TP53 mut, High Ki-67, Complex Karyotype)

  • Consider clinical trials, early novel agents, allogeneic transplant in CR1

Prognosis

  • Median OS: ~8–10 years (modern era); highly heterogeneous
  • 5-year OS: ~65–75% overall; >80% favorable MIPI; <50% high-risk
  • Relapse is common; sequential novel agents (BTKi, venetoclax, PI3Ki, CAR-T) extend survival

Specialized lymphoma center care with access to clinical trials optimizes outcomes.

Lymphoma - Related Articles